PT  - JOURNAL ARTICLE
AU  - Simon R. Mucha
AU  - Siddharth Dugar
AU  - Keith McCrae
AU  - Douglas E. Joseph
AU  - John Bartholomew
AU  - Gretchen Sacha
AU  - Michael Militello
TI  - Coagulopathy in COVID-19
AID  - 10.3949/ccjm.87a.ccc024
DP  - 2020 May 14
TA  - Cleveland Clinic Journal of Medicine
4099  - http://www.ccjm.org/content/early/2020/05/12/ccjm.87a.ccc024.short
4100  - http://www.ccjm.org/content/early/2020/05/12/ccjm.87a.ccc024.full
AB  - COVID-19-associated coagulopathy is common in patients with COVID-19, causing high rates of thrombotic complications that increase the morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings and correlate with severity of illness and risk of thrombosis. Aggressive VTE prophylaxis is paramount for all patients with COVID-19. Patients with very high D-dimer levels (6 times the upper limit of normal, greater than 3,000 ng/mL) have the greatest risk of thrombosis and may benefit from active screening and more intensive VTE prophylaxis.